Assuntos
Fármacos Anti-HIV/uso terapêutico , Dessensibilização Imunológica , Hipersensibilidade a Drogas/complicações , Hipersensibilidade a Drogas/terapia , Proteína gp41 do Envelope de HIV/uso terapêutico , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Fragmentos de Peptídeos/uso terapêutico , Adulto , Fármacos Anti-HIV/efeitos adversos , Dessensibilização Imunológica/métodos , Tolerância a Medicamentos , Enfuvirtida , Evolução Fatal , Proteína gp41 do Envelope de HIV/efeitos adversos , Hepatite C/complicações , Hepatite C/cirurgia , Humanos , Transplante de Fígado , Masculino , Fragmentos de Peptídeos/efeitos adversos , Abuso de Substâncias por Via Intravenosa/complicaçõesRESUMO
OBJECTIVES: To evaluate the efficacy and safety of an update to an anti-emetic protocol in chemotherapy for gynecological tumours. METHOD: Prospective observational study performed over 12 months in a general hospital with 400 beds. We evaluated the efficacy of the old anti-emetic protocol, a new protocol was implemented, and its efficacy was determined. We included patients with gynaecological tumours that sought treatment at the Day Hospital. After each chemotherapy cycle, patients filled out a survey that registered the number and severity of episodes of nausea/vomiting and other adverse effects. The efficacy of treatment was measured as complete response (no nausea or vomit) in the acute phase (first 24h after chemotherapy) and late phase (2-5 days after chemotherapy). We also evaluated whether age, the type of protocol, and the emetogenous power of the different treatment schemes could influence patient response. RESULTS: We analysed 102 chemotherapy cycles under the old protocol (52 patients) and 293 cycles under the new protocol (98 patients). We observed significant differences in complete response rates in the late phase between old and new protocols (36.27% vs 67.38%, P<.0001). The probability of obtaining a complete response using the new protocol was twice as high as with the old protocol in acute emesis (OR=1.85, 95% CI: 1.05-3.24, P=.03) and four times higher in late emesis (OR=4.27, 95% CI: 2.59-7.02, P<.0001). CONCLUSIONS: A greater percentage of complete responses to late emesis was obtained using the new protocol. Age and the low emetogenous power of the treatment schemes were predictive factors for complete response in acute emesis.
Assuntos
Antieméticos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias dos Genitais Femininos/complicações , Vômito/induzido quimicamente , Vômito/prevenção & controle , Adulto , Fatores Etários , Idoso , Antieméticos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Feminino , Neoplasias dos Genitais Femininos/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Valor Preditivo dos TestesRESUMO
Pulmonary hypertension is a difficult-to-diagnose, poor-prognosis disease that may be primary or secondary to other conditions. It is characterized by pulmonary vasoconstriction, in situ thrombosis, and altered endothelial function, which clinically manifests with dyspnea and other disabling symptoms for the patient. Conventional treatment includes oral anticoagulants together with oxygen supplementation, diuretics, and digoxin --according to concurrent conditions-- as well as vasodilators, traditionally calcium antagonists. In recent years novel vasodilators have been developed for use in the treatment of pulmonary hypertension-prostaglandins (epoprostenol, iloprost), endothelin-1 receptor antagonists (bosentan), nitric oxide, and sildenafil, among other drugs under study. However, question marks remain on the management of this disease, and further studies are needed to find a truly effective therapeutic option.
Assuntos
Hipertensão Pulmonar/tratamento farmacológico , Vasodilatadores/uso terapêutico , Árvores de Decisões , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/etiologia , Hipertensão Pulmonar/cirurgiaRESUMO
OBJECTIVES: To analyze the influence on adherence and clinical outcome of the replacement of a previous antiretroviral therapy to a simplified approach using zidovudine, lamivudine, and abacavir (Trizivir) and to assess its economic impact. METHODS: A retrospective study of 75 pretreated, HIV-infected adult patients who received Trizivir from May 2001 to December 2002. Adherence was assessed by dispensation records or medication counting, CD4 lymphocyte counts, and viral load before and six months after medication change was analyzed; finally, the cost of each therapy was assessed in order to calculate the economic impact of medication change. RESULTS: Mean adherence significantly increased a 2.5% after medication change; 16 more patients reached optimal adherence, with an NNT (number of patients requiring therapy change in order to obtain one more adherent) of 4.7. The number of patients with undetectable viral load remained almost similar, and mean CD4 cell counts stayed above 500 cells/mm3 in both periods of time. A great variability in incremental costs was seen, due to the varying costs of the previous treatments, and the influence of five intensification therapies using Trizivir. However, when only simplification regimens were analyzed such variability was reduced, and even became favorable in selected cases. CONCLUSIONS: Changing to a simplification therapy using Trizivir resulted in improved adherence, similar clinical outcomes, and a varying economic impact depending on previous antiretroviral therapy costs.